anti-B7-H3 CAR-T cells

Anti-B7-H3 CAR-T cells are autologous T lymphocytes genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets the B7 homolog 3 (B7-H3, also known as CD276) protein. B7-H3 is an immune checkpoint molecule with limited expression in normal tissues but is highly expressed on the surface of various solid tumors, including glioblastoma, pediatric solid malignancies, ovarian cancer, and liver cancer. The mechanism of action involves the recognition and binding of tumor-expressed B7-H3 by the engineered CAR on T cells, leading to targeted cytotoxicity against tumor cells. Preclinical studies have demonstrated potent antitumor activity in vitro and in vivo models; early-phase clinical trials show safety and preliminary efficacy signals in relapsed or refractory solid tumors such as glioblastoma and pediatric cancers[4][6][1]. Multiple constructs exist using different monoclonal antibody clones for targeting; some versions include additional features like suicide genes or selection markers for enhanced safety or tracking[4][6][2].

Other names

Anti-B7-H3 CAR-T细胞B7H3 CAR T cellsB-7H3 CAR T cellsB 7H3 CAR T cellsB7-H3-specific chimeric antigen receptor T cellsB-7-H3-specific chimeric antigen receptor T cellsB 7-H3-specific chimeric antigen receptor T cells